Unveiling the Potential of UBE2U: A Novel Testicular Tissue Protein as a Drug Target and Biomarker

Target Name: UBE2U

NCBI ID: G148581

UBE2U

Unveiling the Potential of UBE2U: A Novel Testicular Tissue Protein as a Drug Target and Biomarker

UBE2U (Ubiquitous Base-pair Enrichment 2 UniProt Consensus) is a protein that is expressed in human testicular tissue, including seminal vesicles, epididymis, and the urethra. It is a 21.6-kDa protein that belongs to the Ubiquitous Base-pair Enrichment (UBE) family, which is characterized by the presence of a hypervariable region (HVR) in the N-terminus. The HVR is rich in basic and acidic residues, which give the protein its unique structure and function.

Recent studies have identified UBE2U as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and urological infections. In this article, we will delve into the molecular and functional aspects of UBE2U, highlighting its potential as a drug target and biomarker.

Molecular Characterization

UBE2U is a member of the UBE family, which is characterized by the presence of a HVR in the N-terminus. The HVR of UBE2U is rich in basic and acidic residues, including a cluster of alkaline amino acids (Ala-His-Asp-Glu-Asn-Gly-Arg-Gln-Asp-Glu-Asp) in the N-terminus. This HVR is also known as the \"basic region\" and is involved in the protein's localization, stability, and interactions with other proteins.

Expression and Localization

UBE2U is expressed in various human tissues, including testicular tissue, where it is predominantly found in the seminal vesicles, epididymis, and the urethra. It is also expressed in other tissues, including the brain, heart, liver, and muscle. The protein is predominantly nuclear and can also be detected in the cytoplasm of cultured cells.

In addition to its expression in various tissues, UBE2U is also known to localize to specific cellular structures in the testicular tissue. It has been shown to localize to the nuclear and cytoplasmic compartments of testicular epithelial cells and to be involved in the regulation of cell cycle progression.

Function and Potential Therapeutic Applications

The basic region of UBE2U is involved in several cellular processes, including DNA binding, RNA binding, and protein-protein interactions. It has been shown to interact with various proteins, including the transcription factor, TFAS, and the protein, synaptonemal complex (SPP), which is involved in the regulation of meiosis.

In addition to its role in cellular processes, UBE2U is also a potential drug target and biomarker due to its unique structure and function. The HVR of the protein is rich in basic and acidic residues, which make it a potential target for small molecules or antibodies. Furthermore, its localization to specific cellular structures in the testicular tissue makes it a potential biomarker for urological diseases.

Potential Therapeutic Applications

The basic region of UBE2U is a potential drug target due to its unique structure and function. Several studies have shown that the HVR of UBE2U is involved in the regulation of cellular processes, including DNA binding, RNA binding, and protein-protein interactions. This suggests that UBE2U may be a good candidate for small molecules or antibodies that can modulate its function and activity.

In addition to its potential as a drug target, UBE2U also has the potential as a biomarker for various urological diseases, including cancer, neurodegenerative disorders, and urological infections. Its localization to specific cellular structures in the testicular tissue makes it a potential

Protein Name: Ubiquitin Conjugating Enzyme E2 U

Functions: Catalyzes the covalent attachment of ubiquitin to other proteins

The "UBE2U Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UBE2U comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets